Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
IMM-101
i
Other names:
IMM-101, IMM 101, heat-killed whole cell Mycobacterium obuense suspension in borate-buffered saline, NCTC 13365, heat killed M. obuense (NCTC) 13365)
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Immodulon
Drug class:
Dendritic cell activator
Related drugs:
‹
PVS-RIPO (1)
GEN-001 (0)
HER-2 pulsed DC1 (0)
ID-LV305 (0)
ilixadencel (0)
KRAS-EphA-2-CAR-DC (0)
CDX-301 (0)
NC410 (0)
ORB-011 (0)
TP53-EphA-2-CAR-DC (0)
LOAd703 (0)
DC-TC (0)
CDX-1401 (0)
personalized cellular vaccine (0)
PVS-RIPO (1)
GEN-001 (0)
HER-2 pulsed DC1 (0)
ID-LV305 (0)
ilixadencel (0)
KRAS-EphA-2-CAR-DC (0)
CDX-301 (0)
NC410 (0)
ORB-011 (0)
TP53-EphA-2-CAR-DC (0)
LOAd703 (0)
DC-TC (0)
CDX-1401 (0)
personalized cellular vaccine (0)
›
Associations
News
Trials
Filter by
Latest
4ms
COV-IMMUNO: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (clinicaltrials.gov)
P3, N=195, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Apr 2024 --> Dec 2024
4 months ago
Trial completion date
|
IMM-101
4ms
PRIMUS006: A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov)
P2, N=50, Recruiting, Karen Carty
4 months ago
New P2 trial • Metastases
|
Keytruda (pembrolizumab) • gemcitabine • IMM-101
1year
COV-IMMUNO: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (clinicaltrials.gov)
P3, N=195, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Oct 2023 --> Apr 2024
1 year ago
Trial primary completion date
|
IMM-101
over1year
COV-IMMUNO: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (clinicaltrials.gov)
P3, N=195, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Oct 2023
over 1 year ago
Trial completion date • Trial primary completion date
|
IMM-101
2years
Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced Pancreatic Cancer. (PubMed, Cancers (Basel))
Combination therapy with SBRT and a heat-killed mycobacterium vaccine was safe and had an immune-stimulatory effect.
2 years ago
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • ICOS (Inducible T Cell Costimulator) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M)
|
IMM-101
over2years
IMM-101-015: A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma (clinicaltrials.gov)
P2, N=16, Completed, Immodulon Therapeutics Ltd | Active, not recruiting --> Completed | N=26 --> 16 | Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Dec 2021
over 2 years ago
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • IMM-101
almost3years
ANTONIO: Atezolizumab With/Without IMM-101 in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin (clinicaltrials.gov)
P2, N=120, Recruiting, AIO-Studien-gGmbH | Not yet recruiting --> Recruiting
almost 3 years ago
Enrollment open
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tecentriq (atezolizumab) • oxaliplatin • IMM-101
3years
ANTONIO: Atezolizumab With/Without IMM-101 in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin (clinicaltrials.gov)
P2, N=120, Not yet recruiting, AIO-Studien-gGmbH
3 years ago
New P2 trial
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tecentriq (atezolizumab) • oxaliplatin • IMM-101
over3years
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma (clinicaltrials.gov)
P2, N=26, Active, not recruiting, Immodulon Therapeutics Ltd | Recruiting --> Active, not recruiting
over 3 years ago
Clinical • Enrollment closed • Combination therapy • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • IMM-101
almost4years
Safety and efficacy of adding immunotherapy combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer(MEPANC-1) (clinicaltrialsregister.eu)
P2, N=100, Ongoing, Erasmus MC
almost 4 years ago
Clinical • New P2 trial
|
CA 19-9 (Cancer antigen 19-9)
|
IMM-101
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login